SPEGRA TABLET

SPEGRA TABLET

Spegra Tablets is a combination of Dolutegravir, emtricitabine, and tenofovir alafenamide tablets are determined for use apart as a through regimen for the medication of human immunodeficiency virus type 1 (HIV-1) infection. Spegra Tablets is a used to treatment of antiretroviral drug. Dolutegravir is post-exposure prophylaxis. Emtricitabine & Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor for the medication of chronic hepatitis B virus (HBV) disease.

Mechanism of Action:

Spegra Tablets is an HIV-1 antiviral agent. Emtricitabine is a cytidine mate which, when phosphorylated to emtricitabine 5'-triphosphate plays with deoxycytidine 5'-triphosphate for HIV-1 reverse transcriptase. Tenofovir alafenamide presents a 91% lower plasma combination with an intracellular existence of about 20-fold higher when compared to tenofovir disoproxil. Tenofovir alafenamide grows more in peripheral blood mononuclear cells related to red blood cells. Dolutegravir prevents HIV integrase by required to the active site and blocking the string transfer step of retroviral DNA unification in the host cell. As HIV-1 reverse transcriptase combines emtricitabine into producing DNA strands, new nucleotides are incapable to be integrated, leading to viral DNA chain termination. TAF is mostly metabolized intracellular to TFV.

Pharmacokinetics

1.Absorption

When 50 mg of Dolutegravir once daily was orally conduct to HIV-1 contaminate adults, the AUC, Cmax, and Cmin is 53.6 mcg h/mL, 3.67mcg/mL, and 1.11mcg/mL, commonly. Emtricitabine attains a Cmax of 1.8±0.7µg/mL with a Tmax of 1-2 hours and has an AUC of 10±3.1µg*hr/mL. Tenofovir alafenamide produces a lipophilic group that masks the weak charge of the person moiety which increases its oral bioavailability.

2. Distribution

The organization of a dose of 50 mg of Dolutegravir presents a supposed volume of distribution of 17.4 L.The probable central volume of distribution is 42.3L and the incidental The volume of distribution is 55.4L. The volume of distribution of tenofovir alafenamide was higher than 100 L.

3. Metabolism

Dolutegravir is greatly metabolized over three main pathways and it forms no long-lived metabolites. The first pathway is described by the glucuronidation by UGT1A1, the second pathway by carbon oxidation by CYP3A4 and the third pathway is what develops to be a subsequent oxidative defluorination and glutathione combination. Emtricitabine is almost 86% unmetabolized. Tenofovir alafenamide presents important plasma stability and hence, its activation is implementing inside the mark cells.

4. Excretion

Dolutegravir is given almost all total doses is found in a proportion of 53% excreted unaffected in the feces and 31% excreted in the urine. Emtricitabine is 86% regained reclaimed in the urine and 14% recovered in feces.

Contraindication:

Spegra Tablets are contraindicated in patients with former hypersensitivity response to Dolutegravir. The taking dofetilide immunity to the possible for raised dofetilide plasma concentrations and the uncertainty for severe and growth-dangerous actions.

Drug Interaction:

The Suggested dose of Spegra Tablets is one tablet taken orally once daily with or without food. The pediatric patients weighing at least 40 kg (88 lbs.) and creatinine approval were greater than or equal to 30 mL per minute. Spegra Tablets is not suggested in patients with estimated creatinine go-head below 30 mL per minute

Side-Effects:

Nausea, Fatigue Abdominal pain, Vomiting, Anemia decreased platelet count, increased serum creatinin, Diarrhea, Upper respiratory tract infection.

Storage:

Store below 30°C (86°F). Secure from humidity. Distribute only in the original bottle.

Pregnancy & lactation

Spegra Tablets should be used during pregnancy only if the potentiality advantage maintains the potential risk. Breastfeeding is not suggested due to the potential for HIV transmission.

Contact details
Apple Pharmaceuticals
Mobile/Viber/Telegram :+919987711567
WeChat : applepharmaceuticals
Skype : applepharma
qq : 2097734872
Email id :applepharmaceutical@gmail.com
Website : https://myapplepharma.com/

TAFNAT 25mg TABLET

TAFNAT25mg TABLET

Tafnat tablet is a hepatitis B virus (HBV) nucleotide reverse transcriptase inhibitor for the medication of chronic hepatitis B virus (HBV) infection in adults with recompense liver disease. Tafnat tablets taken by orally. Tenofovir alafenamide is a prodrug of tenofovir. Tafnat tablet approximately connected to the commonly used is reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF).

Mechanism of action:

Tafnat tablet presents 91% lower plasma concentration with an intracellular being of about 20-fold higher when related to tenofovir disoproxil. Tafnat tablet acquires further in peripheral blood mononuclear cells related to red blood cells. Once stimulate, tenofovir acts with various systems contains the prevention of viral polymerase, being chain termination, and the blockage of viral synthesis.

Pharmacokinetics:

1. Absorption

Tafnat tablet presents a the lipophilic group that covers the negative charge of the person component which develops its oral bioavailability. Tafnat tablet is deeply stable in plasma and, after the organization of this prodrug; there is a low combination of tenofovir in plasma.

2.Distribution

The volume of distribution of Tafnat tablet was higher than 100 L.

3. Metabolism

Tafnat tablet is recommended to be determined to the person mixture tenofovir by the action of cathepsin A or carboxylesterase 1. Tenofovir alafenamide presents serious plasma establishment and hence, its awakening is performed inside the mark cells.

4.Excretion

Tafnat tablet has been certified to existing a bile expulsion that compares to 47% of the administrate dose and a renal elimination the represents about 36%. From the regained dose in urine, about 75% is represented as unaffected tenofovir followed by uric acid and a small dose of tenofovir alafenamide. In feces, 99% of the recovered dose compare to tenofovir.

Dosage and Administration

The suggested dosage of Tafnat tablet is 25 mg (one tablet) taken orally once daily with food.

Side-Effects:

Headache, Fatigue, Cough, Nausea, Back pain, Abdominal pain, Reduction in bone mineral density, Glycosuria, Creatine kinase elevation, Amylase lipase elevated.

Drug Interaction:

Drug interactions may change to your treatment work or increase your risk for severe side effects.

Uses:

Tafnat tablet is used to treat chronic hepatitis B infection, a viral infection of the liver.

Storage:

Store below 30 °C (86 °F). Keep the bottle tightly closed. Distribute only in the original bottle.

Over Dosage:

Treatment of overdosage with Tafnat tablet consists of a general accessory portion containing monitoring of vital signs as well as consideration of the clinical status of the patient. Tafnat is clearly removed by hemodialysis with an eradication coefficient of almost 54%.

Missed Dose:

If you missed a dose and remember within 18 hours after the scheduled time, take it as soon as you remind. If it is longer than 18 hours after the missed dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

Contact details 
Apple Pharmaceuticals 
Mobile/Viber/Telegram :+919987711567
WeChat : applepharmaceuticals 
Skype : applepharma
qq : 2097734872
Email id :applepharmaceutical@gmail.com
Website : https://myapplepharma.com/